Wacker Chemie AG (LON:0NR4)
London · Delayed Price · Currency is GBP · Price in EUR 63.55
-5.03 (-7.33%)
At close: Aug 1, 2025
Verve Therapeutics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 135.7 | 241 | 313.6 | 1,251 | 806.9 | 189.2 | Upgrade |
Depreciation & Amortization | 498.8 | 472.7 | 418.7 | 402.1 | 403.5 | 402.5 | Upgrade |
Loss (Gain) From Sale of Assets | 9.9 | 8.8 | 12 | -3.4 | 3.3 | 2.6 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | - | - | 0.7 | 1 | Upgrade |
Loss (Gain) on Equity Investments | -4.9 | -19.1 | -49.3 | -200.9 | -62.4 | -34.9 | Upgrade |
Other Operating Activities | 23.4 | -9.6 | 90.8 | 53.4 | 43.3 | 67.9 | Upgrade |
Change in Accounts Receivable | 33.9 | 34.1 | 114.4 | -67.6 | -185.2 | -21 | Upgrade |
Change in Inventory | -254.3 | -368.8 | 159.3 | -493 | -165.9 | 42.5 | Upgrade |
Change in Accounts Payable | -59.9 | -51.9 | -49.2 | 88.6 | 297.4 | - | Upgrade |
Change in Unearned Revenue | -24.7 | -16.4 | -1.3 | 89.1 | 90 | 14.1 | Upgrade |
Change in Other Net Operating Assets | -40 | 19.6 | -72.7 | 6.2 | -167.2 | 209.8 | Upgrade |
Operating Cash Flow | 317.9 | 310.4 | 936.3 | 1,126 | 1,064 | 873.7 | Upgrade |
Operating Cash Flow Growth | -44.39% | -66.85% | -16.81% | 5.74% | 21.83% | 44.41% | Upgrade |
Capital Expenditures | -639 | -651.6 | -639.6 | -561.2 | -321.3 | -226.5 | Upgrade |
Sale of Property, Plant & Equipment | 3.1 | 2.6 | 1.1 | 10.8 | 46.8 | 50.9 | Upgrade |
Cash Acquisitions | -5.8 | -11.6 | -110.4 | -135.8 | -28.8 | - | Upgrade |
Investment in Securities | 208.9 | 209.1 | 662.5 | -15.2 | -336.4 | -607.5 | Upgrade |
Other Investing Activities | 2 | 11.3 | - | - | - | - | Upgrade |
Investing Cash Flow | -430.4 | -435.3 | -107.6 | -701.4 | -639.7 | -783.1 | Upgrade |
Long-Term Debt Issued | - | 623.1 | 407.2 | 315.5 | 2.4 | 518.2 | Upgrade |
Long-Term Debt Repaid | - | -308.3 | -490.5 | -367.4 | -45.9 | -372.9 | Upgrade |
Net Debt Issued (Repaid) | 134.4 | 314.8 | -83.3 | -51.9 | -43.5 | 145.3 | Upgrade |
Common Dividends Paid | -124.2 | -149 | -596.1 | -397.4 | -99.4 | -24.8 | Upgrade |
Other Financing Activities | - | -19.9 | -8.7 | -9.2 | -11 | -3.4 | Upgrade |
Financing Cash Flow | 10.2 | 145.9 | -688.1 | -458.5 | -153.9 | 117.1 | Upgrade |
Foreign Exchange Rate Adjustments | -30.8 | 12 | -21.6 | 2.5 | 29.8 | -17.5 | Upgrade |
Net Cash Flow | -133.1 | 33 | 119 | -31.9 | 300.6 | 190.2 | Upgrade |
Free Cash Flow | -321.1 | -341.2 | 296.7 | 564.3 | 743.1 | 647.2 | Upgrade |
Free Cash Flow Growth | - | - | -47.42% | -24.06% | 14.82% | 240.81% | Upgrade |
Free Cash Flow Margin | -5.68% | -5.96% | 4.63% | 6.87% | 11.97% | 13.79% | Upgrade |
Free Cash Flow Per Share | -6.46 | -6.87 | 5.97 | 11.36 | 14.96 | 13.03 | Upgrade |
Cash Interest Paid | 62.2 | 46.6 | 39.7 | 28.4 | 21.6 | 23.3 | Upgrade |
Cash Income Tax Paid | 92.1 | 60.5 | 58.3 | 392.3 | 151 | 11.3 | Upgrade |
Levered Free Cash Flow | -367.21 | -397.46 | 172.66 | 147.91 | 818.98 | 635.94 | Upgrade |
Unlevered Free Cash Flow | -332.78 | -368.96 | 197.85 | 165.79 | 833.04 | 649.69 | Upgrade |
Change in Net Working Capital | 278.7 | 343.5 | -227 | 578.3 | -103.4 | -313 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.